Overview
This virtual, live activity is designed to be an intimate discussion on a case focused on the management of GVHD. Expert faculty will discuss key considerations for the management of GVHD in a specific treatment context, with a strong emphasis on bringing practical challenges to the faculty for further discussion. Each Oncology On-Call® activity will feature discussion of a different case, with audience members bringing other questions to be addressed.
Target audience
This educational program is directed toward medical oncologists and hematologists who treat and manage patients with hematologic malignancies. Other health care professionals interested in the treatment of hematologic malignancies are invited to participate.
Learning objectives
Upon completion of this activity, participants will be able to:
- Determine how advances in understanding of GvHD biology and pathogenesis have informed novel therapeutic developments for GvHD prevention and management
- Explain the efficacy and safety of standard strategies for the care of patients with acute and chronic forms of GvHD
- Evaluate recent clinical trial evidence in the context of changing paradigms for the management of patients with acute and chronic GvHD
- Describe practical approaches to facilitate the identification and management of treatment-related toxicities in patients at risk for the development of GvHD or who are managed for GvHD.
Benefits of Attending
- Talk with expert faculty in the management of GVHD
- Bring your challenging questions to case discussions
- Learn how to incorporate the multidisciplinary team into assessment and treatment planning for GVHD
Hot Topics
- Novel targeted therapies
- GVHD prophylaxis approaches
- Cell therapy-based treatments
Coming Soon!
Corey Cutler, MD MPH
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Associate Professor, Harvard Medical School
Boston, MA
Disclosures: Consultant: CareDx, Mallinckrodt, Pfizer, Editas Medicine, Deciphera, Jazz Pharmaceuticals, Incyte, Sanofi, Janssen, Bristol Myers Squibb, CTI BioPharma, Equillium, Omeros; Stock/Shareholder: Cimeio Therapeutics
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.